-
For Sarepta, Exondys 51 Might Be Just The Beginning: Credit Suisse Starts At Outperform
Tuesday, October 18, 2016 - 9:56am | 322Read More...Sarepta Therapeutics Inc (NASDAQ: SRPT) shares nearly doubled in September after the FDA granted accelerated approval for the company’s first drug, EXONDYS 51. However, Credit Suisse analyst Alethia Young believes Sarepta is just getting started. Credit Suisse is anticipating the first...
-
Celgene Shares Higher On Positive Crohn's Patient Data
Monday, October 17, 2016 - 3:33pm | 358Read More...Celgene Corporation (NASDAQ: CELG) shares are up a modest 1.2 percent in Mondays session after the company’s United European Gastroenterology Week (UEGW) abstract revealed wide-spread activity for mongersen (GED-301) among Crohn’s patients. Although the full data will not be available...
-
Credit Suisse Hikes TESARO Target Price to $122 On Robust Niraparib Data; Shares Up
Monday, October 10, 2016 - 11:42am | 489Read More...Credit Suisse reiterated its Outperform rating on TESARO Inc (NASDAQ: TSRO) and raised its price target to $122 from $90 to reflect the potential M&A thesis. Excluding M&A, the discounted cash flow-based target remains at $90. Waltham, Massachusetts-based TESARO has an approved product in...
-
Credit Suisse Cuts Gilead Price Target To $95
Wednesday, September 14, 2016 - 10:48am | 278Read More...Gilead Sciences, Inc. (NASDAQ: GILD) shares have dipped 22 percent year-to-date, mostly driven by concerns regarding sustainable levels for the company’s HCV franchise. Credit Suisse’s Alethia Young maintained an Outperform rating on the company, while lowering the price target from...
-
Why Is Biogen Attractive? Credit Suisse Sees 12-24% Upside Takeout Potential
Wednesday, August 3, 2016 - 7:42am | 329Read More...According to reports on CNBC and the Wall Street Journal, several companies, including Allergan plc Ordinary Shares (NYSE: AGN) and Merck & Co., Inc. (NYSE: MRK), have expressed an interest in acquiring Biogen Inc (NASDAQ: BIIB). Credit Suisse’s Alethia Young maintained a Neutral...
-
Upside Surprises More Likely Than Downside for Alexion Pharmaceuticals, Says Credit Suisse
Monday, July 11, 2016 - 8:44am | 257Read More...Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) shares have plummeted 35 percent year-to-date. Credit Suisse’s Alethia Young upgraded the rating on the company from Neutral to Outperform, while reducing the price target from $186 to $165. Following the pullback, Alexion Pharma’s shares...
-
Credit Suisse Cuts BioMarin Price Target As Company Gives Up Revenue For Profit
Monday, June 13, 2016 - 8:15am | 269Read More...BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced the termination of the development of BMN-701 for Pompe disease, besides saying that it was planning to out-license the asset. Credit Suisse’s Alethia Young maintained an Outperform rating for the company, while reducing the price target...
-
Credit Suisse Reiterates Intercept's Lofty $200 Price Target; Ocaliva Will Be A 'Surprisingly Solid Launch'
Tuesday, May 31, 2016 - 3:37pm | 166Read More...Credit Suisse's Alethia Young reiterated her Outperform rating on Intercept Pharmaceuticals Inc (NASDAQ: ICPT) with a price target of $200.00. The reiteration came after Intercept's Octavia product passed FCC approval for treating Patients with PBC. "Ocaliva pricing of $69,350 was roughly in-line...
-
Credit Suisse Initiates Intercept With Outperform, $200 Target
Wednesday, March 30, 2016 - 7:58am | 242Read More...Credit Suisse’s Alethia Young initiated coverage of Intercept Pharmaceuticals Inc (NASDAQ: ICPT) with an Outperform rating and price target of $200. Attractive Entry Point Young mentioned that the company is developing OCA, its lead asset for the treatment of two liver indications, NASH...
-
Why BioMarin's Pipeline Could Be Worth $4 Billion-Plus
Wednesday, January 20, 2016 - 3:31pm | 251Read More...Credit Suisse issued a report on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and initiated coverage on the company due to strength seen in their drug pipeline. Credit Suisse rates BioMarin as Outperform with a $110 price target. Analysts Alethia Young, Eliana Merle and Grant Hesser highlighted...
-
Credit Suisse Bullish On Most Big Pharma Names
Wednesday, January 20, 2016 - 11:34am | 939Read More...Credit Suisse’s Alethia Young initiated coverage of several major pharmaceutical companies, commenting on their valuations, pipelines and more. Analyst Alethia Young initiated coverage of Amgen, Inc. (NASDAQ: AMGN) with an Outperform rating and a $205 price target. Young said that the...
-
Credit Suisse Calls Celgene The Best In Class Near- And Long-Term Growth Story
Wednesday, January 20, 2016 - 9:06am | 271Read More...Celgene Corporation (NASDAQ: CELG) shares were volatile in 2015 and are down 14 percent since January 4. Credit Suisse’s Alethia Young initiated coverage of the company with an Outperform rating and a price target of $149. Celgene’s shares look cheap relative to the company...
-
Why This Analyst Is Cautious On Biogen
Wednesday, January 20, 2016 - 8:49am | 278Read More...Biogen Inc (NASDAQ: BIIB) are down 12 percent since January 4, and trading close to their 52-week low. Credit Suisse’s Alethia Young initiated coverage of the company with a Neutral rating and a price target of $322. More clarity is required on the company’s pipeline and base...
-
Amgen Still Has 'That Biotech Flair'; Credit Suisse Starts At Outperform
Wednesday, January 20, 2016 - 8:36am | 281Read More...Amgen, Inc. (NASDAQ: AMGN) shares are down 5 percent since December 21. Credit Suisse’s Alethia Young initiated coverage of the company with an Outperform rating and a price target of $205. While Amgen is expected to announce near-term pipeline data, PCSK9 outcomes could be positive...
-
What's The Street Think Of Alnylam Pharmaceuticals New Drug Data?
Wednesday, June 24, 2015 - 3:49pm | 287Read More...Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)'s sell-off is unrelated to data the company presented late Tuesday for its prospective hemophilia treatment, an analyst said. Deutsche Bank's Alethia Young attributed the decline to "fast money, selling," and has previously...
